Group items tagged

British pharmaceutical giant GSK said on Saturday (April 15) its oral antibiotic drug to treat uncomplicated urinary tract infections (uUTI) in female adults and adolescents met the main goals in late-stage trials. The drug, gepotidacin, in phase III trials, met its primary goals of being on a par or better than nitrofurantoin, the current standard of care for the treatment of uUTIs, the company said. GSK plans to submit results of the trials to the United States Food and Drug Administration for review later in the second quarter. The drug, if approved, could become the first new type of antibiotic, which is critically important for countering drug-resistant infections, to treat uUTIs in 20 years, the company said. "Gepotidacin, if approved, will offer a much-needed additional oral treatment option for patients at risk of treatment failure associated with resistance or recurrence of uUTI," Chris Corsico, senior vice president of development at GSK, said.

In a bid to amplify the role of pharmacists in clinical services and vaccination programs, the Pharmacists' Defence Association (PDA) has embarked on a groundbreaking collaboration with Aston University. This initiative, funded by Innovate UK Business Connect, aims to explore the feasibility and impact of integrating additional healthcare interventions within community pharmacies. "The Knowledge Transfer Partnership (KTP) research project represents an exciting opportunity to advance the role of pharmacists in patient care," remarked Alison Jones, Director of Policy at PDA. "This project will be an important part of that evolution, supporting individual pharmacists to have more opportunities to practice and so develop more fulfilling careers." Led by the PDA and Aston University, the project will commence imminently, focusing on the Priory Community Pharmacy in Dudley.

Kanabo Group plc, a medical cannabis research and development company, has entered into a partnership with City Dock Pharmacy in London to introduce a walk-in clinic for pain management. The pain clinic will cater to patients who are eligible for alternative therapies (when traditional treatments have failed to deliver improvements), and will offer specialised medicines, including medicinal cannabis. When it opens, the new facility at City Dock Pharmacy in Wapping will become the UK's first walk-in clinic for pain management, but it will also deliver appointment-related services, the companies said. The partnership is part of the London-based company's wider ambition to extend its reach into physical pharmacies throughout the UK, and its plans to replicate this model across other pharmacies.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Monday (29 January 2024) approved the medicine Rezzayo (rezafungin) to treat invasive candidiasis, an infection caused by a yeast called Candida. Invasive candidiasis can pose a serious health risk as it can affect the blood, heart, brain, eyes, bones and other parts of the body. Napp Pharmaceuticals Ltd was granted the marketing authorisation for the medicine based on phase 3 clinical trial data. In the randomised, double-blind, controlled study, more than half of the invasive candidiasis patients who were given a weekly dose of rezafungin were cured at day 14. Among 94 patients who were given a daily dose of caspofungin (another antifungal treatment), 57 of them were cured during the same time.

LloydsPharmacy Clinical Homecare, a leading provider of home healthcare services in the UK, on Monday announced the appointment of Paul Adams as the company's new Chief Executive Officer (CEO). Before assuming his role at LPCH at the end of last year, Adams was leading transformation efforts at DD Group, formerly known as Dental Directory. With a career spanning over two decades, Adams has held influential positions at Diageo, Smith+Nephew, and served as a CEO for various Private Equity companies. He has also co-authored "The Little Black Book of Change." Adams will lead the LPCH's mission to pioneer the delivery of specialist clinical treatment therapies to patients, thereby enhancing patient outcomes within homecare and community settings while improving accessibility.

The NHS England last week released a survey report on the involvement of pharmacy professionals in research, and proposed the implementation of a clinical academic training pathway for pharmacy professionals by 2030. Recommendations were made to support the embedding of research at all stages of a pharmacy professional's career. The report presented the findings of two surveys that NHS England launched in May 2022, one for individual pharmacy professionals and one for organisations, calling for evidence on clinical academic careers in pharmacy. The survey found that only a minority of the pharmacy workforce take up clinical research training opportunities. "Just under a quarter of individual respondents had applied for the National Institute of Health and Care Research (NIHR) or other research project grants, and just under half of the organisational survey respondents had supported individuals to apply for such a grant," it said.

Many people with advanced Parkinson's disease are currently required to take more than 20 pills a day to manage their symptoms, while some necessitate treatment through a permanent feeding tube. Soon, patients will only be required to wear a portable kit to get a continuous dose of the medication delivered into their bloodstream 24 hours a day. This innovative treatment, called Produodopa, will now be made available on the NHS, providing benefit to nearly 1,000 people with advanced Parkinson's disease, according to a BBC report. James Palmer, NHS England's medical director for specialised services, told the publication that the drug's rollout will offer "a vital new option on the NHS for those who aren't suitable for other treatments such as deep brain stimulation." He added that the new therapy will help patients manage their symptoms "more effectively" and improve their quality of life.

The Galien Foundation recently announced the winners of the 2024 Prix Galien UK Awards, with the University of Oxford receiving accolades for its groundbreaking contributions to public sector innovation through the PRINCIPLE and PANORAMIC Trials. These trials, spearheaded by Oxford's team of experts, have set a new standard for scientific innovation aimed at improving global health outcomes. Led by University of Oxford, the PRINCIPLE and PANORAMIC Trials epitomize a remarkable collaboration aimed at combating the COVID-19 pandemic.

In the competitive landscape of healthcare, strategic alliances can be a game-changer. Dr. Dupe, a General Practitioner at Christchurch Clinics, and Baba, a Pharmacist at Christchurch Pharmacy, married for 24-years cultivate their synergy through mental wellbeing walks. Their recent 24 kilometres fundraising walk to support a local hospice - Farleigh Hospice, is one of such. Having met Dupe first in 1994, first as interns at a teaching hospital, now married, the couple offer a comprehensive range of services, including pharmacy, private clinics, homecare services as proprietors of Christchurch Health-centre in Braintree. gp; pharmacist; mental wellbeing walks, healthcare Dupe and Baba in their clinic Dr. Dupe and Pharmacist Baba Akomolafe in their clinic, demonstrating their synergy and dedication to patient care. United by faith, a love for healthcare, and a shared commitment to service the community, their 'Mental Wealth Management' as they call it comprises of daily morning walks covering a distance of six kilometres.